Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08CGU
|
|||
| Former ID |
DCL000496
|
|||
| Drug Name |
Bevacizumab + Rituximab
|
|||
| Drug Type |
Combination drug (Antibody)
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86] | Phase 3 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [1] | ||
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H18ILiN2O3
|
|||
| Canonical SMILES |
[Li+].CCN(CC)CCNC(=O)C1=CC(=C(C=C1)C(=O)[O-])I
|
|||
| InChI |
1S/C14H19IN2O3.Li/c1-3-17(4-2)8-7-16-13(18)10-5-6-11(14(19)20)12(15)9-10;/h5-6,9H,3-4,7-8H2,1-2H3,(H,16,18)(H,19,20);/q;+1/p-1
|
|||
| InChIKey |
CNMYRBKJCDLCHB-UHFFFAOYSA-M
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Roche (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.